Drug Trial Radar · NCT05406362
Assess Safety and Efficacy of VAD044 in HHT Patients
Last checked: Nov 20, 2026Latest source record: Mar 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
75
Actual
Start
Jul 18, 2022
Primary completion
Jan 2027
Study completion Jan 2027
Sponsor
- Lead sponsor
- Vaderis Therapeutics AGIndustry
- Sponsor type
- Industry
- First posted
- Jun 6, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Part I: The purpose of this Phase 1b proof of concept study, randomised, placebo controlled, double blind, multicentre study is to asssess safety and efficacy of 2 doses of VAD044 in adult HHT patients. Part II: The purpose of this open-label extension following the completion of the randomised double blind treatment and follow-up period (Part I of the study) is to assess the long-term safetty, tolerability and efficacy of VAD044 in adult HHT patients.
Conditions
- Hereditary Hemorrhagic Telangiectasia (HHT)
Interventions
VAD044 Part IDrug
capsules to be taken once daily for 12 weeks
VAD044 Part IIDrug
capsules to be taken once daily for 36 months
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part I: Safety and TolerabilityTime frame: 12 weeks
- Part II: Safety and TolerabilityTime frame: 36 months
Locations
7 sites in 6 countries. Site status is shown where the registry gives one.
Massachusetts General Hospital
Boston, Massachusetts
Universitair Ziekenhuis Gent
Ghent, Belgium
Hospices Civils de Lyon
Lyon, France
Ospedale Maggiore di Crema
Crema, Italy
St. Antonius Hospital
Nieuwegein, Netherlands
Hospital Universiati De Bellvitge
Barcelona, Spain
Hospital Universitario Ramón y Cajal
Madrid, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.